Hjem › Hode- og halskreft › Massachusetts
Kliniske studier for Hode- og halskreft i Massachusetts
24 studier for Hode- og halskreft søker deltakere på steder i Massachusetts.
Byer i Massachusetts
Offisiell studietekst (engelsk)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0131, Boston
- Site#0101, Boston
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06788990The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07059884A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06657222Toripalimab With Chemotherapy for Sinus Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 31. aug. 2026 · NCT06940180PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06239220A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jul. 2026 · NCT04545957PDT For Induction Therapy For Head And Neck Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2026 · NCT07214987First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT05768139Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jun. 2026 · NCT07675967Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT06993844Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05726370A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 27. mai 2026 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Worcester
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 26. mai 2026 · NCT06256588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06239194Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- Dana Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT03875716Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
- Brigham and Women's Hospital, Boston
Rekrutterer
Alder 18 til 85 · Alle kjønn · Oppdatert 12. feb. 2026 · NCT07405645Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 26. jan. 2026 · NCT05553782SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. aug. 2025 · NCT04429542Comprehensive Outcomes for After Cancer Health
- Dana Farber Cancer Institute, Boston
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 11. des. 2024 · NCT05349227Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.